Orris

Role of nepafenac eye drop

Reading File
Finding Sources
Searching PubMed

nepafenac ophthalmic NSAID

Reading File
Reading File
Finding Sources
Reading Article

PMID: 39936354

Finding Sources
Reading File
Reading File
Here is a detailed overview of nepafenac eye drops, drawing from Kanski's Clinical Ophthalmology, Goodman & Gilman's, the Wills Eye Manual, and a 2025 meta-analysis (PMID: 39936354).

Nepafenac Eye Drops - Role in Ophthalmology

Drug Class & Formulation

Nepafenac is a topical ophthalmic NSAID prodrug, available as a 0.1% and 0.3% suspension (brand names: Nevanac, Ilevro). It is one of five topical NSAIDs FDA-approved for ocular use alongside flurbiprofen, ketorolac, diclofenac, and bromfenac.

Mechanism of Action

Nepafenac is a prodrug that penetrates the cornea intact and is then converted by intraocular hydrolases to its active metabolite amfenac. Amfenac inhibits both COX-1 and COX-2 enzymes, blocking the conversion of arachidonic acid to prostaglandins. This mechanism provides:
  • Reduced intraocular prostaglandin synthesis
  • Inhibition of the prostaglandin-mediated inflammatory cascade
  • Reduction in vascular permeability (key to preventing macular edema)
The prodrug design allows better corneal penetration than many other topical NSAIDs, leading to higher intraocular concentrations of the active drug.

Indications

1. Postoperative Pain and Inflammation after Cataract Surgery (Primary Indication)

This is the main FDA-approved use. Nepafenac is used perioperatively to control pain, photophobia, and anterior segment inflammation following phacoemulsification.

2. Prevention and Treatment of Cystoid Macular Edema (CME)

This is arguably the most important clinical role:
  • After cataract surgery, prostaglandins cause breakdown of the blood-retinal barrier, leading to CME (Irvine-Gass syndrome)
  • Topical NSAIDs including nepafenac (3 times daily) reduce risk of CME in both non-diabetic and diabetic patients
  • Beneficial even in established long-standing CME; treatment may be required for several months
  • Used as nepafenac 0.3% once daily for CME management
A 2025 systematic review and meta-analysis (24 RCTs, 4,716 eyes) confirmed that nepafenac added to topical steroids is superior to steroids alone in preventing macular swelling after cataract surgery (mean difference in foveal thickness: -11.6 µm at final follow-up; 95% CI [-17.5, -5.8]). Significant BCVA benefit was seen at 3 months. - Almasri et al., 2025

3. Uveitis / Anterior Segment Inflammation

Used as adjunctive therapy alongside topical steroids for:
  • Postoperative uveitis
  • UGH syndrome (uveitis-glaucoma-hyphema) due to IOL irritation
  • Iritis/anterior uveitis

4. Corneal Abrasions and UV Keratitis (Pain Relief)

In the emergency room setting, nepafenac is used for analgesia in:
  • Traumatic corneal abrasions
  • Ultraviolet (UV) photokeratitis
  • Dosing: 1-2 drops, 2-4 times daily

5. Prevention of Intraoperative Miosis

Topical NSAIDs as a class help maintain pupil dilation during cataract surgery, though this is primarily a role for flurbiprofen and ketorolac; nepafenac may provide some benefit.

Dosing Summary

IndicationFormulationDosing
Post-cataract pain/inflammation0.1% suspension3 times daily, starting day before surgery
CME prevention/treatment0.3% suspensionOnce daily
UV keratitis / corneal abrasionEither1-2 drops, 2-4 times daily
Uveitis (adjunct)EitherAs prescribed alongside steroids

Advantages Over Other Topical NSAIDs

FeatureNepafenacBromfenacKetorolac
TypeProdrugActive drugActive drug
PenetrationHigh (prodrug design)Moderate-highModerate
Dosing frequencyOnce or 3x dailyOnce-twice daily4x daily
Onset of actionRequires hydrolysisFasterFaster

Adverse Effects

  • Corneal toxicity (most important): Sterile corneal melt and perforation, particularly in patients with dry eye syndrome, autoimmune ocular surface disease, or elderly patients. All topical NSAIDs carry this risk.
  • Transient burning/stinging on instillation
  • Blurred vision (due to suspension formulation)
  • Conjunctival hyperemia
  • Rarely: delayed wound healing, foreign body sensation
Warning: Use with caution in patients with pre-existing ocular surface disease, dry eye, or rheumatologic conditions affecting the eye due to the risk of corneal melt.

Clinical Position

Nepafenac is used primarily in combination with topical steroids (e.g., prednisolone acetate 1% QID) rather than as monotherapy, particularly for:
  • Perioperative cataract surgery regimens
  • Prevention of CME (especially in diabetic patients undergoing cataract surgery, who are at higher risk)
The latest evidence (2025 meta-analysis, PMID: 39936354) confirms that adding nepafenac to the standard steroid regimen significantly reduces foveal thickening and improves visual outcomes at 3 months post-surgery.
Sources:

What about use in 21 year old person having -7D lens number & having mild symptoms of blackness but normal looking retina

Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Searching Images

high myopia fundus retina myopic degeneration

A composite of diagnostic ophthalmological images featuring wide-field fundus photography and fundus autofluorescence (FAF) in patients with early-onset high myopia (eoHM) related to ARR3 variants. Panels A-H display wide-field fundus photographs showing a predominantly tessellated fundus appearance, characterized by increased visibility of the large choroidal vessels due to thinning of the retinal pigment epithelium and choriocapillaris. In younger patients (A-F, ages 2-20Y), the peripheral retina appears relatively preserved. Panel C demonstrates a normal FAF scan with no conspicuous hyper- or hypo-autofluorescence, indicating stable metabolic activity of the retinal pigment epithelium. Panels G and H (ages 30Y and 32Y) include magnified insets of the peripheral retina, highlighting age-related progression marked by lattice degeneration and distinctive white dots. Clinical metadata indicates high myopic refractive errors ranging from -6.00DS to -15.50DS. The collection illustrates the spectrum of myopic maculopathy and peripheral retinal changes associated with X-linked female-limited inheritance in ARR3-related myopia.

A composite of diagnostic ophthalmological images featuring wide-field fundus photography and fundus autofluorescence (FAF) in patients with early-onset high myopia (eoHM) related to ARR3 variants. Panels A-H display wide-field fundus photographs showing a predominantly tessellated fundus appearance, characterized by increased visibility of the large choroidal vessels due to thinning of the retinal pigment epithelium and choriocapillaris. In younger patients (A-F, ages 2-20Y), the peripheral retina appears relatively preserved. Panel C demonstrates a normal FAF scan with no conspicuous hyper- or hypo-autofluorescence, indicating stable metabolic activity of the retinal pigment epithelium. Panels G and H (ages 30Y and 32Y) include magnified insets of the peripheral retina, highlighting age-related progression marked by lattice degeneration and distinctive white dots. Clinical metadata indicates high myopic refractive errors ranging from -6.00DS to -15.50DS. The collection illustrates the spectrum of myopic maculopathy and peripheral retinal changes associated with X-linked female-limited inheritance in ARR3-related myopia.

This composite diagnostic image illustrates pathological myopia in a 57-year-old patient. Panel A is a fundus photograph showing severe myopic retinal degeneration and chorioretinal atrophy at the posterior pole, exposing the underlying white sclera. A distinct grayish oval depression (macular scleral pit) is visible inferior to the macula. Panel B displays B-scan ultrasonography (top) and A-scan (bottom), revealing a significant posterior staphyloma characterized by an abnormal elongation and posterior bulging of the ocular wall. Panel C presents an Enhanced Depth Imaging Optical Coherence Tomography (EDI-OCT) cross-section, demonstrating a deep, crater-like pit measuring approximately 958 μm in depth. The OCT scan highlights extreme thinning of the neurosensory retina and partial loss of the retinal pigment epithelium and choroid within the pit area. These findings collectively demonstrate a macular scleral pit (MSP) associated with high axial myopia and posterior staphyloma.

This composite diagnostic image illustrates pathological myopia in a 57-year-old patient. Panel A is a fundus photograph showing severe myopic retinal degeneration and chorioretinal atrophy at the posterior pole, exposing the underlying white sclera. A distinct grayish oval depression (macular scleral pit) is visible inferior to the macula. Panel B displays B-scan ultrasonography (top) and A-scan (bottom), revealing a significant posterior staphyloma characterized by an abnormal elongation and posterior bulging of the ocular wall. Panel C presents an Enhanced Depth Imaging Optical Coherence Tomography (EDI-OCT) cross-section, demonstrating a deep, crater-like pit measuring approximately 958 μm in depth. The OCT scan highlights extreme thinning of the neurosensory retina and partial loss of the retinal pigment epithelium and choroid within the pit area. These findings collectively demonstrate a macular scleral pit (MSP) associated with high axial myopia and posterior staphyloma.

This medical image displays findings from a 62-year-old patient with pathological myopia and metamorphopsia. Panel A is a color fundus photograph showing severe myopic retinal degeneration. Key features include extensive chorioretinal atrophy, choroidal lacquer cracks, and marked retinal thinning, exposing the white underlying sclera. A red arrow identifies a Macular Scleral Pit (MSP) located inferotemporally to the macula. This MSP is a well-demarcated, oval, gray-white lesion approximately one optic disc diameter in size, with linear retinal vessels visible across its base. Panel B is a cross-sectional Optical Coherence Tomography (OCT) scan corresponding to the lesion. It reveals a deep, crater-like excavation that extends through the thinned retina and choroid into the sclera. The OCT shows a sharp depression located approximately 30 ̀̀m from the fovea centralis. There is a focal area of hyperintensity at the base of the pit beneath the neurosensory retina, though no active neurosensory detachment or defects are observed. These findings illustrate the structural complications associated with axial elongation in high myopia.

This medical image displays findings from a 62-year-old patient with pathological myopia and metamorphopsia. Panel A is a color fundus photograph showing severe myopic retinal degeneration. Key features include extensive chorioretinal atrophy, choroidal lacquer cracks, and marked retinal thinning, exposing the white underlying sclera. A red arrow identifies a Macular Scleral Pit (MSP) located inferotemporally to the macula. This MSP is a well-demarcated, oval, gray-white lesion approximately one optic disc diameter in size, with linear retinal vessels visible across its base. Panel B is a cross-sectional Optical Coherence Tomography (OCT) scan corresponding to the lesion. It reveals a deep, crater-like excavation that extends through the thinned retina and choroid into the sclera. The OCT shows a sharp depression located approximately 30 ̀̀m from the fovea centralis. There is a focal area of hyperintensity at the base of the pit beneath the neurosensory retina, though no active neurosensory detachment or defects are observed. These findings illustrate the structural complications associated with axial elongation in high myopia.

This is a well-defined clinical scenario that needs careful unpacking. Here is a structured clinical analysis:

Clinical Scenario Analysis: 21-year-old, -7D Myopia, "Blackness," Normal Retina

Step 1 - What Does "Blackness" Mean Here?

In a young highly myopic patient, "mild symptoms of blackness" most likely refers to one of these:
SymptomDescriptionLikely Cause
FloatersDark spots/threads/cobwebs drifting in visionVitreous syneresis/liquefaction (most common)
ScotomaFixed dark patchRetinal or optic nerve issue
Momentary blackoutsTransient vision darkeningVascular (amaurosis fugax) or optic nerve
Shadow/curtainPeripheral darknessEarly retinal detachment (urgent)
At -7D, this patient is classified as high myopia (≥ -6D). High myopia causes early and accelerated vitreous degeneration - the vitreous gel undergoes syneresis (liquefaction and collapse) at a much younger age than in normal eyes.

Step 2 - Why the Retina Looks Normal

A "normal-looking retina" on routine examination is actually reassuring but not conclusive. In high myopia with floaters, the common cause is vitreous syneresis - the vitreous itself is degenerating, not the retina. The retinal surface appears intact. However, this same process puts the patient at risk for future retinal tears as the liquefied vitreous can tug on areas of vitreoretinal adhesion.
Additionally, some early pathological changes in high myopia can be missed on a non-dilated exam:
  • Lattice degeneration in the periphery
  • Early lacquer cracks (not always visible without detailed fundus exam)
  • Early posterior vitreous detachment (PVD) not yet causing a retinal tear

Step 3 - Pathologic Myopia Context (-7D)

At -7D, this patient qualifies as having pathologic/degenerative myopia (threshold is ≥ -6D or axial length ≥26.5 mm). The Wills Eye Manual highlights the following features and risks:
Structural changes in high myopia:
  • Posterior staphyloma (abnormal posterior bulging of sclera)
  • Myopic crescent adjacent to the optic disc
  • Macular pigmentary abnormalities and Fuchs spots
  • Lacquer cracks (breaks in Bruch's membrane)
  • Peripheral lattice degeneration
  • Vitreal degeneration/syneresis
Risks this patient carries:
  • Rhegmatogenous retinal detachment (RRD) - vitreous traction can tear the thinned retina
  • Choroidal neovascularization (CNV)
  • Macular schisis or macular hole (from staphyloma traction)
  • Glaucoma (IOP measurement may be underestimated by standard tonometry in highly myopic eyes)
  • Wills Eye Manual, Section 11.22 - Pathologic/Degenerative Myopia

Step 4 - Role of Nepafenac in THIS Patient

Nepafenac is NOT indicated for this presentation.
The "blackness" this patient experiences is almost certainly vitreous-origin floaters from syneresis - a mechanical/structural issue, not an inflammatory or prostaglandin-mediated condition. Nepafenac works by blocking COX enzymes to reduce prostaglandin-driven inflammation and macular edema. It has no role in:
  • Vitreous degeneration or floaters
  • Vitreoretinal traction
  • Myopia-related peripheral retinal thinning
  • Prevention of retinal detachment
The only scenario where nepafenac might be considered in a young myopic patient is if there was a concurrent inflammatory condition (e.g., uveitis-related CME, or post-surgical CME if they underwent any ocular procedure).

Step 5 - What SHOULD Be Done for This Patient

Immediate Workup:

  1. Dilated fundus examination with indirect ophthalmoscopy + scleral indentation - to look for peripheral retinal breaks, lattice degeneration, or early detachment (the "normal retina" may have been assessed without full dilation/indentation)
  2. Slit lamp biomicroscopy with 90D lens - assess macula for schisis, CNV, lacquer cracks
  3. B-scan ultrasonography if the media is not clear - assess posterior staphyloma and vitreous
  4. OCT macula - to detect foveal schisis, sub-retinal fluid, early CNV that is not visible clinically
  5. Visual fields - to detect any scotoma pattern
  6. Applanation tonometry (note: standard Schiotz/Tono-pen may underestimate IOP in high myopia; use Goldmann)

Management Based on Findings:

FindingAction
Vitreous floaters only, no retinal pathologyReassurance, observation, return if acute floaters/flashes/curtain
Lattice degenerationProphylactic laser photocoagulation (controversial - done if symptomatic)
Retinal break/tearUrgent laser/cryotherapy
Retinal detachmentUrgent surgical repair (scleral buckle / vitrectomy)
CNV detected on OCT/IVFAAnti-VEGF (bevacizumab/ranibizumab)
Macular schisisMonitor; vitrectomy if progressive
GlaucomaIOP-lowering therapy

Lifestyle Advice:

  • Wear polycarbonate safety goggles for sports - high myopia significantly increases choroidal rupture risk from minor trauma
  • Return urgently if: sudden increase in floaters, flashes of light (photopsia), or a curtain/shadow in vision - these are red flag signs of retinal tear or detachment
  • Follow-up every 6-12 months even if asymptomatic

Summary

QuestionAnswer
Is nepafenac indicated?No - not for vitreous floaters or myopic degeneration
What is the likely cause of "blackness"?Vitreous syneresis / floaters from high myopia
Is the "normal retina" finding sufficient?Not without a full dilated exam with scleral indentation
What is the priority?Rule out retinal breaks, detachment, and early macular complications with full workup
When would nepafenac ever be used in myopia?Only if concurrent CME/uveitis/post-surgical inflammation is present
High myopia fundus with early-onset myopic changes showing tessellated fundus and peripheral lattice degeneration
Wide-field fundus showing high myopia changes - tessellated fundus with increased visibility of choroidal vessels, and peripheral lattice degeneration in older patients. A 21-year-old at -7D is at the early stage of this spectrum.
The bottom line: This patient needs a thorough dilated retinal examination and OCT - not nepafenac. The drug has no therapeutic role in floaters or vitreous degeneration from myopia.
This is a shared conversation. Sign in to Orris to start your own chat.